Learn with Us: Goodwin + KPMG @ JPMorgan Symposium at the St. Regis Hotel

Description

Registration closed! If you would like to be put on the waiting list, please click here. We will contact you if space becomes available.

Learn with Us: Goodwin + KPMG @ JPMorgan Symposium at the St. Regis Hotel When: Wednesday, January 15, 8:30 am - 6:15 pm PT Where: St. Regis, 125 3rd Street, San Francisco,

 Learn with us at this special symposium co-hosted by Goodwin + KPMG on Wednesday, January 15, 8:30 am - 6:15 pm. The symposium will provide the latest insights and perspectives from healthcare and life sciences industry professionals and will address key topics including:

 •Disconnected to Connected: New Frontiers in Digital Diagnostics & Medtech •Europe Unleashed: 2020 Vision for EU Growth Stage Venture Funding and Maximizing Returns through Structured M&As •Startups Break Through: Knowing the Best IPO Strategy •Trends in Biopharma: Evaluating and Partnering New Technologies and Emerging Business Models •Mergers and Acquisitions: The Brave New World of Antitrust in Life Sciences M&A 

Goodwin + KPMG @ JPMorgan Symposium Full Agenda 

8:30 am – 8:45 am Welcome Remarks •Mitch Bloom, Chair, Life Sciences Practice, Goodwin •Kristin Ciriello Pothier, Global Healthcare and Life Sciences Strategy Leader, KPMG (Moderator) Burst 1 | New Frontiers in Digital Diagnostics & Medtech 

8:50 am – 9:05 am Current State of the Healthcare Sector & Regulations •Roger Cohen, Partner, Goodwin

 9:10 am – 9:55 am New Frontiers in MedTech Space on the Global Stage: What are the Challenges in IP, Regulatory and Commercial •Kristin Ciriello Pothier, Global Healthcare and Life Sciences Strategy Leader, KPMG (Moderator) •Nicholas Mitrokostas, Partner, Goodwin •Stefan Scherer, Global Head of Experimental Medicine, GlaxoSmithKline (GSK) •Joseph Zaccaria, Client Growth Director, TrialSpark •Reena L. Pande, MD MSc, Chief Medical Officer, AbleTo 

10:00 am – 10:45 am Panel: Issues Facing Therapeutic Companies Using ML and AI in Drug Discovery Methods •Danielle Lauzon, Partner, Goodwin (Moderator) •David Berry, General Partner, Flagship; CEO, Integral •Dan Housman, Co-founder, CTO Graticule, Co-founder Courage Therapeutics Keynote Speech 

10:55 am – 11:40 am Keynote Speaker - Stéphane Bancel, CEO, Moderna 

11:40 am – 12:10 pm Lunch Break Burst 2 | Europe Unleashed 

12:10 pm – 12:40 pm The Evolving Landscape for Growth-Stage Venture Funding in Europe •Sophie McGrath, Partner, Goodwin (Moderator) •Francesco De Rubertis, Co-Founder and Partner, Medicxi •Dirk Kersten, General Partner, Forbion 

12:45 pm – 1:15 pm Maximizing Returns through Structured M&As •Graham Defries, Partner, Goodwin (Moderator) •Erik van den Berg, CEO, AM-Pharma •Geert-Jan Mulder, Co-Founder and Managing Partner, Forbion •Maarten de Jong, Managing Director, Moelis & Company Burst 3 | Knowing the Best IPO Strategy

 1:20 pm – 1:40 pm 2020 Vision for the IPO Market •Amit Sinha, Managing Director, Investment Banking Division, Goldman Sachs 

1:40 pm – 2:10 pm Traditional US IPO Route: “The Two Minute Drill” to Complete a Successful IPO in the First Six Months of the Year •Janet Lehman, National Leader, VC Life Sciences, KPMG (Moderator) •Tom Koncsics, Partner, KPMG •Michael Bison, Partner, Goodwin •Jack Cassel, Vice President, Nasdaq •Amit Sinha, Managing Director, Investment Banking Division, Goldman Sachs

 2:15 pm – 2:45 pm Hong Kong IPO: Seizing Opportunities in a New Emerging Market for Biotech IPOs •Wendy Pan, Partner, Goodwin Hong Kong (Moderator) •Irene Chu, Partner, Head of New Economy and Life Sciences, Hong Kong, KPMG China •Michael Chan, Head of International Issuer Business, Hong Kong Exchanges and Clearing Limited (HKEX) •Bin Li, Founder and Chief Investment Officer, Lake Bleu Capital 

2:50 pm – 3:20 pm Alternatives to U.S. IPO: Reverse Mergers and Direct Listings •Deepa Rich, Partner, Goodwin (Moderator) •Gerry Schemidt, Partner, Audit, KPMG •Mitchell H. Gold, Executive Chairman & CEO, Alpine Immune Sciences •David Snyder, Chief Financial Officer, Exicure 3:20 pm – 3:30 pm Coffee & Networking Burst 4 | Trends in Biopharma

 3:30 pm – 4:10 pm Evaluating and Partnering New Technologies and Emerging Business Models •Kingsley Taft, Partner, Goodwin (Moderator) •Jeff Stoll, Principal, National Life Sciences Strategy Leader, KPMG •Nicholas Pullen, Ph.D., Executive Director of Inflammation & Immunology Integrative Sciences, Bristol-Myers Squibb Burst 5 | Mergers and Acquisitions 

4:15 pm – 5:15 pm The Brave New World of Antitrust in Life Sciences M&A •Stuart Cable, Partner, Goodwin (Moderator) •Lisa Haddad, Partner, Goodwin •Andrea Murino, Partner, Goodwin 

5:15 pm – 6:15 pm Cocktails & Networking